Shares of IPSEN (OTCMKTS:IPSEY – Get Free Report) gapped down prior to trading on Monday . The stock had previously closed at $36.3596, but opened at $34.34. IPSEN shares last traded at $34.34, with a volume of 300 shares.
Analyst Upgrades and Downgrades
Several analysts have recently weighed in on the stock. BNP Paribas cut shares of IPSEN to an “underperform” rating in a research report on Wednesday, November 26th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of IPSEN in a research report on Monday, November 3rd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold”.
Check Out Our Latest Analysis on IPSEN
IPSEN Price Performance
IPSEN Company Profile
Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.
The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).
Further Reading
- Five stocks we like better than IPSEN
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- Do not delete, read immediately
- This stock gets a 94 out of 100
- The $100 Trillion AI Story No One Is Telling You
- 3 Overlooked Deductions to Help Potentially Minimize Capital Gains Tax
Receive News & Ratings for IPSEN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IPSEN and related companies with MarketBeat.com's FREE daily email newsletter.
